Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
v. Mitchell (Birmingham, United Kingdom), K. Howles (Birmingham, United Kingdom), L. White (Birmingham, United Kingdom), A. Pillai (Birmingham, United Kingdom), A. Mansur (Birmingham, United Kingdom). Efficacy and safety of Mepolizumab in a real world severe asthma cohort.. 2523

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of azithromycin in a real world severe asthma cohort Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 One year of mepolizumab in severe asthma in Italy: efficacy and safety Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Long term efficacy and safety of omalizumab in patients with allergic asthma-A real life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Efficacy and safety of omalizumab in real-life practice in India Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Real world outcomes of Mepolizumab for severe asthma in Wales a retrospective analysis. Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006 Efficacy of antifibrotics in chronic hypersensitivity pneumonitis. A 3 year real-life observational study Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Study to evaluate clinical burden related with oral corticosteroids treatment of severe asthma in Spain (LEVANTE) Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020